Trials / Completed
CompletedNCT05422378
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
A Phase 1 Study to Evaluate the Safety and Tolerability of Subcutaneous Injection of STP705 in Adult Subjects Undergoing Abdominoplasty
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Sirnaomics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Dose-ranging, randomized, double-blind, vehicle-controlled study
Detailed description
Subject will receive a single injection for each treatment which all 3 test article concentrations and both injection volumes and the vehicle for a total of 7 treatments. Subjects will receive test articles in 3 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STP705 | STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually. |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-02-03
- Completion
- 2023-06-27
- First posted
- 2022-06-16
- Last updated
- 2024-03-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05422378. Inclusion in this directory is not an endorsement.